双嘧达莫联合厄贝沙坦对IgA肾病的疗效及其安全性分析

目的探究双嘧达莫联合厄贝沙坦对Ig A肾病的疗效及其安全性。方法采取回顾性分析方法对遵义医学院第五附属(珠海)医院2013年7月—2016年7月Ig A肾病患者88例资料进行收集分析,随机分为单药组和联合组。单药组采用单纯厄贝沙坦治疗;联合组采用双嘧达莫联合厄贝沙坦治疗。比较两组患者Ig A肾病治疗效果;治疗前后24 h尿蛋白、血肌酐;不良反应发生率。结果联合组患者Ig A肾病治疗效果比单药组高,P0.05;治疗前两组患者24 h尿蛋白、血肌酐差异不显著,P0.05;联合组治疗后24 h尿蛋白、血肌酐比单药组好,P0.05;联合组不良反应发生率和单药组差异不显著,P0.05。结论双嘧达莫联合厄贝沙坦对Ig A肾病的疗效及其安全性良好,可改善肾功能,无明显副作用,值得推广。

Analysis of Dipyridamole Combined with Irbesartan Treatment on IgA Nephropathy and its Safety

Objective To explore the effect of dipyridamole combined with irbesartan on IgA nephropathy and its safety.Methods Retrospective methods analysis was performed on 88 patients with IgA nephropathy in our hospital from July 2013 to July 2016, Single drug group were treated with irbesartan treatment;combination group received dipyridamole combined with irbesartan in the treatment of.Comparison of two groups of patients with IgA nephropathy treatment effect before and after treatment for 24 hours urine protein, serum creatinine.Results The therapeutic effect of the combined group of patients with IgA nephropathy than the single drug group, P<0.05;two groups of patients before treatment and 24 hours urine protein, serum creatinine was not significant, P>0.05;combined treatment group after 24 hours urine protein, serum creatinine than the single drug group, P<0.05;united group of adverse reaction difference and the rate of single drug group was not significant, P>0.05.Conclusion Dipyridamole combined with irbesartan treatment on IgA nephropathy and its safety is good, can improve renal function and no obvious side effects, worthy of promotion.